Therapeutics

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

Drug is prescribed as adjunctive therapy for those with glaucoma

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

The study, conducted with Tufts Medical Center, represents a breakthrough showing that Microdose Array Print technology can provide similar benefits of non-preserved medications.

The latest announcement comes after the previously granted ODD for polihexanide in acanthamoeba keratitis by the FDA and EMA.

Dr. Raymond Douglas discusses the real-world adherence to teprotumumab as a treatment for thyroid eye disease.

TearSolutions Inc. is preparing to conduct two trials, one in a primary Sjögren’s Syndrome patient population and the second in a potentially less severe general dry eye population for the treatment of DED.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

The NGF0121 study will enroll 100 patients and will use Schirmer's test and the Symptom Assessment Questionnaire in Dry Eye questionnaire as its co-primary endpoints to measure improvement in signs and symptoms of dry eye over time.

Kato Pharmaceuticals will study the efficacy of Resolv ER for the treatment of vitreomacular attachment.

Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.

After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

During the Glaucoma 360 New Horizons Forum, the spotlight was cast upon sustained release injectables, including innovations that have been flourishing over the past year despite, or perhaps because of, a continuing worldwide pandemic.

Jay S. Duker, MD, who presented data at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, noted that previously treated patients showed a significantly reduced treatment

The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.

During a presentation at the Bascom Palmer Eye Institute's Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition conference, David S. Boyer, MD, explained that the drug, which is being considered to treat diabetic retinopathy, renal disease, and age-related macular degeneration, is intended to be an alternative therapy to monthly chronically administered intravitreal injections of anti-VEGF drugs.

Ora Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, speak with Ophthalmology Times®' Sheryl Stevenson to discuss some of the cutting-edge advancements in therapies and diagnostics for the treatment of glaucoma patients.

Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times®' Sheryl Stevenson on what attendees can expect from this year's annual meeting.

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Presbyopia-correcting drops represent a whole new product category—one with a lot of upsides for clinicians who want to help their patients see well at all distances.

NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.

According to investigators, the implant can provide a sustained infusion of drug to the retina

A team of investigators has conducted ocular pharmacokinetic studies, including metabolism, providing valuable information for ocular drug development.

The future of this age-related condition is bright and in focus.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.